Teva Pharmaceutical Industries Limited
TEVA
$26.88
$0.160.60%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.48B | 4.18B | 3.89B | 4.23B | 4.33B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.48B | 4.18B | 3.89B | 4.23B | 4.33B |
| Cost of Revenue | 2.18B | 2.07B | 2.01B | 2.11B | 2.18B |
| Gross Profit | 2.30B | 2.10B | 1.88B | 2.12B | 2.15B |
| SG&A Expenses | 973.00M | 959.00M | 919.00M | 952.00M | 924.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 9.00M | 5.00M | 2.00M | 28.00M | -19.00M |
| Total Operating Expenses | 3.41B | 3.28B | 3.18B | 3.34B | 3.33B |
| Operating Income | 1.07B | 894.00M | 709.00M | 893.00M | 1.00B |
| Income Before Tax | 648.00M | 204.00M | 294.00M | -247.00M | -321.00M |
| Income Tax Expenses | 214.00M | -78.00M | 74.00M | 28.00M | 69.00M |
| Earnings from Continuing Operations | 434.00M | 282.00M | 220.00M | -275.00M | -390.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.00M | -- | -6.00M | 58.00M | -47.00M |
| Net Income | 433.00M | 282.00M | 214.00M | -217.00M | -437.00M |
| EBIT | 1.07B | 894.00M | 709.00M | 893.00M | 1.00B |
| EBITDA | 1.32B | 1.15B | 953.00M | 1.16B | 1.26B |
| EPS Basic | 0.38 | 0.25 | 0.19 | -0.19 | -0.39 |
| Normalized Basic EPS | 0.45 | 0.35 | 0.26 | 0.42 | 0.36 |
| EPS Diluted | 0.37 | 0.24 | 0.18 | -0.19 | -0.39 |
| Normalized Diluted EPS | 0.45 | 0.35 | 0.25 | 0.42 | 0.36 |
| Average Basic Shares Outstanding | 1.15B | 1.15B | 1.14B | 1.13B | 1.13B |
| Average Diluted Shares Outstanding | 1.16B | 1.16B | 1.16B | 1.13B | 1.13B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |